RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bachem Holding Stock

Bachem Holding Equity 2024

Bachem Holding Equity

1.32 B CHF

Ticker

BANB.SW

ISIN

CH0012530207

WKN

914589

In 2024, Bachem Holding's equity was 1.32 B CHF, a 12.9% increase from the 1.17 B CHF equity in the previous year.

Bachem Holding Aktienanalyse

What does Bachem Holding do?

The Bachem Holding AG is a leading provider of peptides and biochemical agents for the pharmaceutical and biotechnological industry. The company was founded in 1971 in Bubendorf, Switzerland, and has been listed on the Swiss stock exchange since 1998. The company's history began with the founding of Bachem Chemie GmbH by Peter Grogg, a former chemical engineer at Ciba-Geigy. Grogg started the company with a focus on peptide synthesis, an area that was still in its infancy at the time. Over time, Bachem expanded its core business by entering into other areas such as peptide formulation, plant extract manufacturing, and nucleotide synthesis. Today, the company has around 1,400 employees worldwide and operates production and research facilities in Europe, North America, and Asia. Bachem is considered one of the largest peptide manufacturers globally and supplies customers in over 100 countries. The business model of Bachem Holding AG is heavily focused on research and development (R&D). The company invests approximately 15% of its revenue annually in R&D to maintain and expand its leading position in peptide chemistry and biochemical agents. These investments have allowed Bachem to offer a wide range of products and services that meet various customer requirements. The company operates several business segments, including peptides and biochemicals, pharmaceutical contract manufacturing and GMP manufacturing, generic drugs, research services, and products for the diagnostics market. The peptides and biochemicals segment is the core of the company and includes a wide range of peptides, amino acids, peptide libraries, peptide-drug conjugates, synthetic proteins, and bioactive peptides. Bachem also manufactures synthetic peptide kits and customized peptides for research and development. The company is also active in pharmaceutical contract manufacturing, offering customized manufacturing services for bioactive peptides, synthetic drugs, oligonucleotides, and drug-drug conjugates. Customers can benefit from synthesis development to commercial production of active substances. Bachem has also positioned itself in the generic drug market, offering a wide range of peptide-based generics such as buserelin, leuprorelin, and triptorelin. The generic drugs segment was expanded in 2015 through the acquisition of the American biotechnology company American Peptide Company. In addition to manufacturing peptides and biochemical agents, Bachem also provides research services, including peptide synthesis, peptide conjugation with drugs, analysis of protein-protein interactions, and identification of peptide libraries. The company is also active in the diagnostics market, offering a wide range of peptides and antibodies for use in diagnostic products for research and clinical applications. In summary, the Bachem Holding AG is a leading provider of peptides and biochemical agents for the pharmaceutical and biotechnological industry. The company heavily invests in research and development and offers a wide range of products and services to meet various customer requirements. Bachem Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Bachem Holding's Equity

Bachem Holding's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bachem Holding's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bachem Holding's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bachem Holding's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bachem Holding’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bachem Holding stock

What is the equity of Bachem Holding this year?

Bachem Holding has equity of 1.32 B CHF this year.

What was the equity of Bachem Holding compared to the previous year?

The equity of Bachem Holding has increased/decreased by 12.9% increased compared to the previous year.

What impact does a high equity have on investors of Bachem Holding?

A high equity is advantageous for investors of Bachem Holding as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Bachem Holding?

A low equity can be a risk for investors of Bachem Holding, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Bachem Holding affect the company?

An increase in equity of Bachem Holding can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Bachem Holding affect the company?

A reduction in equity of Bachem Holding can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Bachem Holding?

Some factors that can affect the equity of Bachem Holding include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Bachem Holding so important for investors?

The equity of Bachem Holding is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Bachem Holding take to change the equity?

To change equity, Bachem Holding can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Bachem Holding pay?

Over the past 12 months, Bachem Holding paid a dividend of 0.38 CHF . This corresponds to a dividend yield of about 0.52 %. For the coming 12 months, Bachem Holding is expected to pay a dividend of 0.4 CHF.

What is the dividend yield of Bachem Holding?

The current dividend yield of Bachem Holding is 0.52 %.

When does Bachem Holding pay dividends?

Bachem Holding pays a quarterly dividend. This is distributed in the months of May, May, May, May.

How secure is the dividend of Bachem Holding?

Bachem Holding paid dividends every year for the past 26 years.

What is the dividend of Bachem Holding?

For the upcoming 12 months, dividends amounting to 0.4 CHF are expected. This corresponds to a dividend yield of 0.55 %.

In which sector is Bachem Holding located?

Bachem Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bachem Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bachem Holding from 4/30/2024 amounting to 0.4 CHF, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.

When did Bachem Holding pay the last dividend?

The last dividend was paid out on 4/30/2024.

What was the dividend of Bachem Holding in the year 2023?

In the year 2023, Bachem Holding distributed 0.35 CHF as dividends.

In which currency does Bachem Holding pay out the dividend?

The dividends of Bachem Holding are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bachem Holding

Our stock analysis for Bachem Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bachem Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.